2019
Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development
Kaffman A, White JD, Wei L, Johnson FK, Krystal JH. Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development. Methods In Molecular Biology 2019, 2011: 3-22. PMID: 31273690, PMCID: PMC6895673, DOI: 10.1007/978-1-4939-9554-7_1.Peer-Reviewed Original ResearchConceptsPreclinical researchAnimal modelsPsychiatric conditionsLower clinical success ratesClinical success rateCommon psychiatric conditionsPsychiatric clinical trialsClinical trialsNew pharmacotherapiesMore effective interventionsPreclinical workPsychiatric disordersPsychiatric pathophysiologyMental illnessSystematic reviewEffective interventionsAnimal experimentsDrug development processSuccess rateDrug developmentHuman psychopathologyPharmaceutical companiesPredictive validityLarge pharmaceutical companiesAnimals
2008
Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.
Krishnan-Sarin S, O'Malley S, Krystal JH. Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. Alcohol Research 2008, 31: 400-7. PMID: 23584013, PMCID: PMC3860468.Peer-Reviewed Original ResearchConceptsAlcohol dependenceCurrent treatment optionsAlcohol-drinking behaviorDifferent neurochemical systemsAdjunctive treatmentModest efficacyTreatment optionsNew medicationsNew pharmacotherapiesMedicationsHealth problemsNeurochemical systemsPharmacotherapyTreatmentGreat needCertain genesNaltrexoneAlcoholismDisulfiramDrinkers